The Potential Impact of Home OCT on nAMD Management

This new imaging modality may help physicians identify optimal treatment intervals quickly and with greater confidence.

By: Anat Loewenstein, MD, MHA, Mathew W. MacCumber, MD, PhD

Retinal Physician January 1, 2025 Vol 22, Issue January/February 2025 Page(s): 8-10

1

The FDA authorized the first home optical coherence tomography (OCT) device on May 16, 2024, impacting neovascular age-related macular degeneration (nAMD) management.
2

Home OCT allows patients to capture retinal images at home, which are analyzed by AI for biomarkers indicating fluid presence, enhancing disease management.
3

The technology provides high temporal clarity of disease dynamics, enabling quicker and more confident treatment decisions for nAMD.
4

Home OCT facilitates efficient treatment extension intervals, allowing for single-step adjustments based on near-daily imaging data.
5

This imaging modality serves as a safety net, enabling timely interventions for fluid recurrence while reducing patient burden in nAMD management.

1